UP!
|
Type
|
Public |
|---|---|
| Industry | Biomedicine |
| Founder | Edward O. Lanphier II |
| Headquarters | Richmond, California, USA |
|
Number of employees
|
84 |
| Website | http://www.sangamo.com |
Sangamo BioSciences (NASDAQ: SGMO) is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene.
Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.29 | -0.29 |
| Q1 2022 | 2022-05-05 | -0.30 | -0.30 |
| Q4 2021 | 2022-02-24 | -0.26 | -0.26 |
| Q3 2021 | 2021-11-04 | -0.33 | -0.33 |
| Q2 2021 | 2021-08-05 | -0.33 | -0.33 |
| Q1 2021 | 2021-05-04 | -0.32 | -0.32 |
| Q4 2020 | 2021-02-24 | -0.29 | -0.29 |
| Q3 2020 | 2020-11-04 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-05 | -0.26 | -0.26 |
| 2016-06-09 | Reiterated Rating | Jefferies Group | Buy | $14.00 |
| 2016-05-06 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2016-05-03 | Initiated Coverage | Wells Fargo | Buy | |
| 2016-05-03 | Initiated Coverage | Wells Fargo & Co. | Buy | |
| 2016-03-03 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2016-02-10 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2016-02-10 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $16.00 |
| 2016-01-04 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2015-12-22 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2015-12-17 | Initiated Coverage | Janney Montgomery Scott | Buy | $15.00 |
| 2015-12-08 | Reiterated Rating | Wedbush | Buy | $30.00 |
| 2015-12-03 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $16.00 |
| 2015-12-03 | Initiated Coverage | Wells Fargo | Outperform | |
| 2015-12-02 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2015-10-23 | Initiated Coverage | Jefferies Group | Buy | $12.00 to $14.00 |
| 2015-09-28 | Reiterated Rating | Piper Jaffray | Buy | $17.00 |
| 2015-09-28 | Reiterated Rating | Piper Jaffray Cos. | Buy | $17.00 |
| 2015-09-11 | Reiterated Rating | Piper Jaffray | Buy | $17.00 |
| 2015-09-04 | Reiterated Rating | Cowen and Company | Buy | |
| 2015-09-02 | Lower Price Target | Jefferies Group | Buy | $22.00 to $12.00 |
| 2015-09-02 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $22.00 to $16.00 |
| 2015-09-02 | Reiterated Rating | Wedbush | Buy | $30.00 |
| 2015-08-07 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $22.00 |
| 2015-08-07 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2015-06-05 | Reiterated Rating | Piper Jaffray | Overweight | $17.00 |
| 2015-05-19 | Reiterated Rating | BMO Capital Markets | Outperform | $19.00 |
| 2015-05-14 | Set Price Target | Wedbush | Buy | $30.00 |
| 2015-04-23 | Set Price Target | Wedbush | Buy | $30.00 |
| 2015-04-22 | Initiated Coverage | BMO Capital Markets | Outperform | $19.00 |
| 2015-03-01 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2015-02-11 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2015-02-04 | Initiated Coverage | Wedbush | Buy | $29.00 |
| 2015-01-27 | Initiated Coverage | Wedbush | Buy | $29.00 |
| 2015-01-12 | Reiterated Rating | Wedbush | Outperform | $29.00 |
| 2014-09-23 | Initiated Coverage | Jefferies Group | Buy | $22.00 |
| 2014-09-10 | Boost Price Target | Wedbush | $27.00 to $28.00 | |
| 2014-08-01 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $22.00 |
| 2014-03-12 | Boost Price Target | JMP Securities | Outperform | $22.00 to $27.00 |
| 2014-01-09 | Boost Price Target | Wedbush | $22.00 | |
| 2013-11-05 | Boost Price Target | Wedbush | Outperform | $13.00 to $15.00 |
| 2013-10-23 | Boost Price Target | Lazard Capital Markets | Buy | $16.00 to $20.00 |
| 2013-05-03 | Initiated | BioLogic Equity Research | Sell | |
| 2011-02-23 | Reiterated | JMP Securities | Mkt Outperform | $9 to $12 |
| 2009-10-19 | Initiated | Brean Murray | Sell | $4 |
| 2009-10-07 | Reiterated | Leerink Swann | Outperform | $9 to $11 |
| 2009-08-25 | Reiterated | JMP Securities | Mkt Outperform | $13 to $15 |
| 2009-04-14 | Downgrade | Cantor Fitzgerald | Buy to Hold | |
| 2009-02-23 | Reiterated | Leerink Swann | Outperform | $6 to $9 |
| 2009-02-05 | Upgrade | Merriman Curhan Ford | Neutral to Buy | |
| 2008-11-20 | ||||
| 2008-11-11 | Reiterated | Brean Murray | Sell | $4 to $2 |
| 2008-11-11 | Downgrade | Piper Jaffray | Buy to Sell | |
| 2008-11-11 | Downgrade | Merriman Curhan Ford | Buy to Neutral | |
| 2008-10-16 | Initiated | Merriman Curhan Ford | Buy | |
| 2008-08-26 | Reiterated | Leerink Swann | Outperform | $18 to $17 |
| 2008-05-29 | Initiated | Brean Murray | Sell | $5 |
| 2008-05-01 | Reiterated | JMP Securities | Mkt Outperform | $18 to $24 |
| 2008-02-06 | Reiterated | JMP Securities | Strong Buy | $30 to $18 |
| 2007-12-05 | Reiterated | Cantor Fitzgerald | Buy | $17 to $27 |
| 2016-06-09 | Reiterated Rating | Jefferies Group | Buy | $14.00 |
| 2016-05-06 | Reiterated Rating | Wedbush | Outperform | $30.00 |
| 2016-05-03 | Initiated Coverage | Wells Fargo | Buy | |
| 2016-05-03 | Initiated Coverage | Wells Fargo & Co. | Buy | |
| 2016-03-03 | Reiterated Rating | Wedbush | Outperform | $30.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SGMO 149 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 14.26M |
| WASATCH ADVISORS INC | 13.12M |
| Vanguard Group, Inc | 12.73M |
| STATE STREET CORP | 6.97M |
| CREDIT SUISSE AG/ | 3.80M |
| Nuveen Asset Management, LLC | 3.36M |
| BlackRock Fund Advisors | 3.22M |
| DIMENSIONAL FUND ADVISORS LP | 3.07M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.38M |
| BlackRock Institutional Trust Company, N.A. | 1.85M |
| RENAISSANCE TECHNOLOGIES LLC | 1.67M |
| JPMORGAN CHASE & CO | 1.54M |
| GOLDMAN SACHS GROUP INC | 1.45M |
| NORTHERN TRUST CORP | 1.21M |
| D. E. Shaw & Co., Inc. | 1.20M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| RA CAPITAL MANAGEMENT, LLC Former 10% Owner. | 5.40% (3683000) | ACHN / ARDM / BSTC / DRNA / DSCI / SGMO / |
| LANPHIER EDWARD O II President & CEO | 1.72% (1175094) | SGMO / |
| LARSON JOHN WILLIAM | 0.31% (214660) | SGMO / WAGE / |
| Wolff Henry Ward Exec VP & CFO | 0.30% (206829) | ABIO / CALA / PTLA / SGMO / |
| NICHOL GEOFFREY Executive Vice President, R&D | 0.23% (159676) | SGMO / |
| Gregory Philip D Vice President, Research & CSO | 0.17% (116410) | BLUE / SGMO / |
| ANDO DALE G VP, Therapeutic Dev. & CMO | 0.16% (107328) | SGMO / |
| Macrae Sandy President and CEO | 0.05% (31500) | SGMO / |
| Herberts Curt A. III Senior VP & CBO | 0.02% (14625) | SGMO / |
| Mento Steven J | 0.02% (11832) | CNAT / SGMO / |
| Conner Edward R. Sr. VP & Chief Medical Officer | 0.01% (8125) | SGMO / |
| Yi Kathy Senior VP & CFO | 0.01% (7250) | SGMO / |
UM